The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients

Glucagon-like peptide-1 receptor agonists (GLP1RA) have been shown to improve glucose control and diabetes-related comorbidities in patients without solid organ transplants. The effectiveness, safety, and tolerability of GLP1RA after kidney transplantation have not been adequately studied. METHODS....

Descripción completa

Detalles Bibliográficos
Autores principales: Kukla, Aleksandra, Hill, Jennifer, Merzkani, Massini, Bentall, Andrew, Lorenz, Elizabeth C., Park, Walter D., D’Costa, Matthew, Kudva, Yogish C., Stegall, Mark D., Shah, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Kidney Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004635/
https://www.ncbi.nlm.nih.gov/pubmed/32095510
http://dx.doi.org/10.1097/TXD.0000000000000971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004635/
https://www.ncbi.nlm.nih.gov/pubmed/32095510
http://dx.doi.org/10.1097/TXD.0000000000000971

Ejemplares similares